Best Vascular Endothelial Growth Factor Inhibitor for carcinoma, non-small-cell lung
3 Vascular Endothelial Growth Factor Inhibitor drugs indicated for carcinoma, non-small-cell lung, ranked by our independent rating. The current highest-rated is avastin. Compare them with all treatments for carcinoma, non-small-cell lung or the full Vascular Endothelial Growth Factor Inhibitor class. Not medical advice — always consult a professional.
Top vascular endothelial growth factor inhibitor for carcinoma, non-small-cell lung: 1. Avastin · 2. Alymsys · 3. Avzivi
| # | Drug | Rating | Type | Typical price | |
|---|---|---|---|---|---|
| 1 | Avastin | 72/100 | Prescription | — | View → |
| 2 | Alymsys | 70/100 | Prescription | — | View → |
| 3 | Avzivi |
Full ranking · 3 drugs
Frequently asked
- What is the best vascular endothelial growth factor inhibitor for carcinoma, non-small-cell lung?
- By our independent rating, avastin currently ranks highest among Vascular Endothelial Growth Factor Inhibitor drugs used for carcinoma, non-small-cell lung. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.
- Which vascular endothelial growth factor inhibitor drugs treat carcinoma, non-small-cell lung?
- pharmaranks lists 3 Vascular Endothelial Growth Factor Inhibitor products indicated for carcinoma, non-small-cell lung, per FDA drug-label data — each independently rated and ranked above.
- How are these ranked?
- By our independent score, currently based on FDA regulatory recall-safety data (the methodology blends additional sources as they come online). See the How we rate page.